Department of Urology

May 26, 2017

Visiting professor Dr. Sia Daneshmand welcomed as 9th annual Endowed Hirschler Lecturer

Dr. Siamak Daneshmand

Dr. Siamak Daneshmand

The Department of Urology was delighted to host Dr. Siamak Daneshmand, Associate Professor of Urology, Director of Urologic Oncology, and Director of Clinical Research at Keck School of Medicine of USC, for the 9th Annual Endowed Hirschler Lecture as part of the 2017 Resident & Fellow Research Day. Dr. Daneshmand presented “Innovations in urology and how to incorporate research into daily practice.”

Dr. Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to the USC Institute of Urology in 2010 as Director of Urologic Oncology. Dr. Daneshmand also directs the urologic oncology (SUO) fellowship.

Dr. Daneshmand’s clinical interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases in the country. Additionally, Dr. Daneshmand has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels.

Among his research interests, Dr. Daneshmand focuses on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion. He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience.

Dr. Daneshmand serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) and the AUA/SUO Guideline Committee on non-muscle invasive bladder cancer. He is a member of Alpha Omega Alpha medical honor society, and has been designated one of “America’s Top Cancer Doctors” for numerous consecutive years. He is an active member of the Society of Urologic Oncology, has presented over 300 abstracts at scientific meetings and authored over 200 peer-reviewed articles, reviews, and book chapters.